Mikhail Blagosklonny is a professional involved in the study of cancer and the aging process. Currently, he is based at the Roswell Park Cancer Institute where he teaches oncology. Mikhail was a student at First Pavlov State Medical University, which is located in St. Petersburg and graduated with an M.D. and Doctor of Philosophy in tentative medicine and cardiology. He went on to become an Associate Professor at New York Medical College in 2002, where he taught Medicine. He then moved to Ordway Research Institute, where he was the senior scientist up to 2009. He joined his current work place after his stint at Ordway.
Mikhail Blagosklonny’s Areas of Study
Blagosklonny has a vast interest in cancer studies. His research focuses on marked cancer therapies capable of preventing normal cells from damages as a result of radioactive rays or chemotherapy. He also researches on the aging mechanism (biogerontology) and anti-aging management. Mikhail Blagosklonny is also interested in molecular and cellular biology as well as medical investigations. He has carried out research on cellular senescence, signal transduction, cell cycle and anti-cancer therapeutics. He has so far managed to reveal a number of potential targets that slow-down age-related ailments and the aging course.
Blagosklonny’s Editorial Works
He is also an assistant editor of biology and cancer therapy. He is also the founding and chief editor of International Journal of cancer, Autophagy, American Journal of Pathology, Cell death and differentiation as well as cancer research. Oncotarget refers to a medical journal that is published on a weekly basis. It was established in 2010, and covers the area of oncology research extensively. Its chief editors are Mikhail Blagosklonny and Andrei V. Gudkov. Mikhail has managed to write over 170 articles on his research areas. Visit ResearchGate.Net to learn more about Mikhail’s latest work.
Hypothesis on TOR Signalling’s Possible Role in Cancer and Aging
Stemming from his interest in studying aging and cancer, Mikhail came up with a hypothesis based on TOR signaling. He put forward a theory that TOR can play a possible role in the management of both aging and cancer. Mikhail proposed the use of rapamycin to extend human life.